ASCO Annual Meeting Poster: Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
ASCO Annual Meeting Abstract: Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
AACR 2019 Meeting: Interim results from CLASSICAL-Lung, a phase 1b/2 Study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC
Poster: Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Updated interim results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC patients
Poster: The Fifth International Cancer lmmunotherapy Conference in Paris, France Interim results from pepinemab in combination with avelumab in NSCLC patients who progressed on prior anti-PDx therapy (CLASSICAL – Lung)
CLASSICAL_ASCO 2019 poster_FINAL.pdf
Invited Podium Presentation: The Fifth International Cancer lmmunotherapy Conference in Paris, France Interim results from pepinemab in combination with avelumab in NSCLC patients who progressed on prior anti-PDx therapy (CLASSICAL – Lung)